Hikal share price today

Hikal Ltd's share price was ₹222.63 at the close on 4 November 2026. It has been falling for 6 weeks. That is 1.2% above its average price over the last 200 trading days. In the last 52 weeks it traded between ₹156 and ₹253, and at that close it sat 69% of the way up from that low.

A share price tends to move through four phases: moving sideways (stage 1), rising (stage 2), stalling near a high (stage 3) and falling (stage 4). Today Hikal Ltd is in stage 4. The phase helps read everything below.

Over the past 13 weeks it has done better than the NIFTY 500, and it has stayed ahead for 2 weeks in a row.

Over the last 11 years the share price moved +143% while the NIFTY 500 moved +251%, so it is behind the index over that whole period. The chart above shows the 13-week comparison for every week.

This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row.

One change stood out: profit grew again in the June 2026 quarter.

1. Profit grew again in the June 2026 quarter

   Profit was ₹-7 crore, +67% on a year earlier (₹-22 crore), after 4 quarters of decline.

   Why: Profit improved because the company got a single gain from reversing money it had set aside for a labour code rule.

   Next results: check whether FDA remediation costs start falling and pending Pharma approvals come through, since management expects operating profit to improve substantially once those costs go away.

   From the earnings call on 6 Aug 2026.

For April to June 2026 (the quarter ended 30 June 2026), Hikal reported revenue of ₹403 crore, up 5.9% from ₹380 crore a year earlier, and a loss of ₹7.40 crore.

Hikal results: April to June 2026 against a year earlier

The next results, for July to September 2026, are due by 14 November 2026: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter).

Hikal's management discussed these results on a call held on 6 August 2026; what it said is further down this page.

From the company's reported quarterly results (quarter ended 30 June 2026). Revenue and profit in ₹ crore.

Hikal closed at ₹222.63 on 4 November 2026, down 4.0% from ₹231.87 a year earlier (7 November 2025) and down 58.5% over five years. Its highest weekly close since March 2016 was ₹696.40 on 13 August 2021.

Hikal share price: then and now

Weekly closing prices, adjusted for splits and bonuses so every price is on today’s share count. Each change is the move from that price to the 4 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes.

562 weekly closes from 11 March 2016 to 4 November 2026.

4 Nov 2026: Hikal closed at ₹222.63, up 5.2% on the week and up 2.1% on the month. 4 Sep 2026: ex-date for a dividend of ₹0.40 a share.

Earlier

• 6 Aug 2026: Hikal held its results call for April to June 2026. Management guided: July to September 2026 revenue and operating profit expected to show substantial on a year earlier growth, with momentum accelerating in H2.
• Results for April to June 2026: Revenue up 5.9% on a year earlier.
• 17 Feb 2026: ex-date for an interim dividend of ₹0.20 a share.

Hikal paid ₹0.60 a share in regular dividends in the 12 months to 5 November 2026 (2 payments), a yield of 0.27% at the ₹222.63 close on 4 November 2026. The last was a dividend of ₹0.40 a share, ex-date 4 September 2026.

Hikal dividends since 1 April 2021

Amounts as the company declared them on the NSE. A dividend goes to whoever owns the shares before the ex-date.

Not in its latest year. Hikal Ltd paid out 0% of its profit as dividends in FY26. It did pay a dividend in 12 of its last 13 reported years, so there is a history but no current dividend.

From the NSE corporate-actions record, read 5 November 2026.

On the call for April to June 2026, held on 6 August 2026, Hikal's management guided: July to September 2026 revenue and operating profit expected to show substantial on a year earlier growth, with momentum accelerating in H2.

“Once the FDA remediation goes away by end of this year, next year onwards the EBITDA will start improving even more substantially.”Sameer Hiremath, on the call for April to June 2026

What management guided

• FY27 revenue growth 14-16% and operating profit growth 25-30%, led by strong Pharma and marginal Crop growth.
• Crop Protection Q2 expected better than Q1 and Q3 further improved; longer-term growth framed as marginal to high-single-digit.
• USFDA reinspection hoped toward end FY27, subject to closing open issues; FY28 operating profit expected to improve substantially as remediation costs fall away, with pending approvals and filings able to ramp Pharma revenue.
• Company revenue yearly growth 15-16% and Pharma yearly growth 18-19% from FY28 onward; DMF filings planned at 6-7 annually.

Management’s own plans and goals, from our notes of the call. A plan is not a result.

Source: the call transcript.

From the call for April to June 2026, 6 August 2026.

When Hikal reports July to September 2026, these are the 4 checks that show whether the story is still on course. First: USFDA reinspection and closure of open issues - check timing, outcome and release of pending Pharma approvals.

Hikal is on one of our India lists: Pharma stocks.

Hikal Ltd posted a net loss of ₹7.4 Cr in the Jun 2026 quarter. The full FY26 year was a loss of ₹49.0 Cr. That loss is 1.8% of the quarter's revenue. The same quarter a year earlier lost ₹22.4 Cr. 4 of the last 12 reported quarters were loss-making.

Net profit is what is left after every cost, interest and tax. Earnings per share, dividends and book value all grow from it.

For the full year, FY26 profit was −₹49.0 Cr (−153.8% on the year before).

On average over the last four quarters, profit changed −165.4% and revenue −4.8%. Profit is growing slower than sales: rising costs are taking part of the growth.

Hikal Ltd reported ₹403 Cr of revenue in the Jun 2026 quarter, +5.9% on the same quarter a year earlier. Over 10 years it has grown 6.3% a year on average. The last full year, FY26, came in at ₹1,713 Cr. The last four reported quarters add to ₹1,735 Cr.

Revenue is everything the company billed its customers in the period.

FY26 revenue was ₹1,713 Cr, −7.9% on the year before.

Recent pace: the last four quarters grew −4.8% on average, against 6.3% a year over the longer run, so this year is growing slower than its own long-run rate.

Is growth speeding up? Revenue over the last 12 months grew −5.4%, against −1.9% a year over the last 8 quarters (rolling over).

Hikal Ltd's operating margin was 9.2% in the Jun 2026 quarter, 2.6 percentage points higher than the same quarter a year ago. Across 13 years it has been between 13.0% and 23.0%. The latest quarter is below every full year in that period.

Operating margin is what is left from every ₹100 of sales after the costs of running the business, before interest and tax. It shows pricing power and cost control.

Why the margin moved: operating margin changed +2.6 percentage points on the year while gross margin changed +3.8 points. So the gain came mostly from the gross margin, which means input costs and prices charged.

Over the last 3 years, 327% of Hikal Ltd's reported profit came in as cash from its operations, so the profit is backed by cash. In FY26 it brought in ₹302 Cr of operating cash against −₹49.0 Cr of profit. After ₹106 Cr of spending on assets, ₹196 Cr was left over as free cash.

The profit and loss account shows what was earned. The cash-flow statement shows the cash that actually came in. Comparing operating cash flow with profit is one of the best checks that a profit is real.

Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year.

Why 327% of profit came in as cash: the cash cycle got 20 days longer between FY21 and FY26, so more of each rupee of profit waits in the business before it arrives.

What to look at next: no single use of cash stands out. The next section checks both the cash tied up in daily operations and the spending on assets.

Hikal Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 138 days in FY26, up from 118 days in FY21. It spent ₹483 Cr on assets over the last 3 years. Customers take 94 days to pay, and stock sits for 172 days on average.

Working capital is the cash tied up between paying suppliers and getting paid. Debtor days: how long customers take to pay. Inventory days: how long stock sits. The cash cycle: the whole loop, in days of sales.

At FY26 sales of ₹1,713 Cr, each day of that cycle ties up about ₹4.7 Cr, so roughly ₹648 Cr is tied up in the business at any time.

FY26: customers took 94 days to pay and stock sat for 172 days, about 5.7 months of sales sitting as stock, for a full cycle of 138 days, longer than FY21's 118.

The full loop: cash goes out to suppliers and production on day 0. Stock sits for 172 days. Customers pay about 94 days after that. Suppliers are paid at 128 days. Together that makes the 138-day cycle.

Spending on assets: ₹483 Cr over the last 3 years, against ₹416 Cr of depreciation (the yearly wear and tear on existing assets). So it is building a little beyond replacing what wears out. Work still in progress is ₹94.0 Cr (FY26): assets paid for that are not earning yet.

In short: neither the daily cycle nor new spending is soaking up the cash, so the picture is fairly clean.

Hikal Ltd's P/E is 64.6×, near the high end of its own history: higher than 90% of past readings. Its usual P/E (the middle reading) is 37.5×, over 11 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth.

P/E is the share price divided by a year's profit per share: how many rupees the market pays for each rupee of yearly profit.